Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)

Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C

(2015) Ranka Vukotic et al.   DIGESTIVE AND LIVER DISEASE

Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection

(2015) Graham R. Foster et al.   GASTROENTEROLOGY

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

(2015) Eric Lawitz et al.   HEPATOLOGY

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

(2015) David R. Nelson et al.   HEPATOLOGY

P0840 : Safety and effectiveness of sofosbuvir-based regimens for the treatment of hepatitis C genotype 3 and 4 infections: Interim analysis of a prospective, observational study

(2015) S. Alqahtani et al.   JOURNAL OF HEPATOLOGY

P0867 : Efficacy evaluation of 24 week SOF + RBV in a heterogeneous, real-world population of genotype 3 HCV patients; Data from the trio network

(2015) K. Kowdley et al.   JOURNAL OF HEPATOLOGY

EASL Recommendations on Treatment of Hepatitis C 2015

(2015)   JOURNAL OF HEPATOLOGY

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

(2015) Graham R. Foster et al.   NEW ENGLAND JOURNAL OF MEDICINE

In VitroActivity and Resistance Profile of Dasabuvir, a Nonnucleoside Hepatitis C Virus Polymerase Inhibitor

(2014) Warren Kati et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

(2014) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients

(2013) A. H. Talal et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

(2013) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

(2013) Eric Lawitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)

(2012) Fiona McPhee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study

(2012) Christophe Moreno et al.   JOURNAL OF HEPATOLOGY

Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202)

(2012) Oliver Lenz et al.   JOURNAL OF HEPATOLOGY

Hepatitis C Virus Genotypes in Clinical Specimens Tested at a National Reference Testing Laboratory in the United States

(2011) J. J. Germer et al.   JOURNAL OF CLINICAL MICROBIOLOGY

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis

(2011) G. Nkontchou et al.   JOURNAL OF VIRAL HEPATITIS

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C

(2011) Mark S. Sulkowski et al.   Nature Reviews Gastroenterology & Hepatology

Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus

(2010) Michael J. Sofia et al.   JOURNAL OF MEDICINAL CHEMISTRY

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C

(2009) Pierre-Yves Bochud et al.   JOURNAL OF HEPATOLOGY

Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis

(2008) A. ANDRIULLI et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission

(2008) Muhammad Idrees et al.   BMC INFECTIOUS DISEASES

Changing HCV genotypes distribution in Poland—Relation to source and time of infection

(2008) Slawomir Chlabicz et al.   JOURNAL OF CLINICAL VIROLOGY

Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006

(2008) Francois Roman et al.   WORLD JOURNAL OF GASTROENTEROLOGY